News FDA fast-tracks Sanofi's experimental chlamydia vaccine Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.
News FDA starts review of Sanofi's MS hope tolebrutinib Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.
News Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.
News Can Dupixent plug treatment gap in bullous pemphigoid? The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.
News First biosimilar fast-acting insulin reaches US market Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.
News Sanofi, J&J abandon trial of E coli vaccine after poor data Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by E coli looks all but defunct after they abandon a phase 3 trial.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl